MADRIGAL PHARMACEUTICALS, INC. Cash and Cash Equivalents, Fair Value Disclosure
MADRIGAL PHARMACEUTICALS, INC. (MDGL) had Cash and Cash Equivalents, Fair Value Disclosure of $292.88 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes
us-gaap:CashAndCashEquivalentsFairValueDisclosure · last filed 2026-07-30
- 2026-06-30: Cash and Cash Equivalents, Fair Value Disclosure $292.88M.
- 2026-03-31: Cash and Cash Equivalents, Fair Value Disclosure $232.19M.
- 2025-12-31: Cash and Cash Equivalents, Fair Value Disclosure $203.78M.
- 2025-09-30: Cash and Cash Equivalents, Fair Value Disclosure $300.69M.
| Period end | Cash and Cash Equivalents, Fair Value Disclosure |
|---|---|
| 2026-06-30 | $292.88M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $232.19M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $203.78M 10-Q · filed 2026-07-30 |
| 2025-09-30 | $300.69M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $191.19M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $188.65M 10-Q · filed 2025-05-01 |
| 2024-12-31 | $105.02M 10-K · filed 2026-02-19 |
| 2024-09-30 | $237.68M 10-Q · filed 2024-10-31 |
| 2024-06-30 | $499.60M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $622.52M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $99.92M 10-K · filed 2025-02-26 |
| 2022-12-31 | $331.55M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |